78 results about "Chronic stressor" patented technology

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

This invention is directed to pharmaceutical compositions and methods for treating a disorder or condition selected from the group consisting of depression, anxiety disorders, phobias, avoidant personality disorder, eating disorders, chemical dependencies, Parkinson's diseases, obsessive-compulsive disorder, negative symptoms of schizophrenia, cognitive dysfunction related to schizophrenia, premenstrual syndrome, stress-induced incontinence, headache, neuropathic pain, chronic pain, urinary incontinence, post-traumatic stress disorder, chronic stress, acute stress, fibromyalgia, depression comorbid with fibromyalgia, obesity, migraine and a combination thereof in a mammal. The methods in one embodiment comprise administering to a mammal in need of treatment for the disorder or condition: (i) at least one serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined in the specification; and (iii) a pharmaceutically acceptable carrier. The pharmaceutical compositions and methods of the invention are also useful for preventing a relapse associated with one of the foregoing disorders or conditions, and for treating a symptom associated with one of the foregoing disorders or conditions, wherein the symptom is selected from the group consisting of cognitive dysfunctions and somatic complaints.

A method of treating a disorder by nasally administering methylcobalamin, with or without folinic acid. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dislexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel.

A method of treating a disorder by lollipop administering methylcobalamin, with or without folinic acid by direct delivery to the trigeminal nerve. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dyslexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel. A lollipop for treating a psychological or neuro-physiological disorder and method of making thereof.

A preparation method of chronic hepatic injury complicated with stress depression rat model comprises selecting male Wistar rat (body weight of 180-220 g), acclimating for one week, performing open field test ethology screening, and selecting rat having close integration; normally drinking and eating for the first week to the fourth week, and performing hypodermic injection of 40% CCL4 1ml/kg (twice per week); normally drinking and eating from the fifth to the twelfth week, performing hypodermic injection of 40% CCL4 1ml/kg (twice per week), and performing gastric perfusion of normal saline (one time per day); normally drinking and eating in the thirteenth week, and performing gastric perfusion of normal saline (one time per day); performing open field test in the fourteenth to sixteenth week (one rat per cage), normally drinking and eating, performing gastric perfusion of normal saline (one time per day), and offering chronic stress stimulation; and weighing in 112th day, and performing sweet water consumption and open field test. The preparation method provides reference for modeling research of chronic hepatic injury complicated with stress depression, provides effective experiment base for clinical diagnosis of hepatopathy complicated with depression, and provides experimental verification means for the research of drug for treating the hepatopathy complicated with depression.

The invention relates to a study method using capillary electrophoresis and UPLC-MS (ultra performance liquid chromatography - mass spectrometry) to analyze a regulating function of PQQ (pyrroloquinoline quinone) on catecholamine neurotransmitter, and belongs to the technical field of biological analysis. The method comprises the following steps of extracting brain tissues by anion solid-phase extraction, measuring the change of content of catecholamine in a mouse brain of a chronic stress induced depression model and the change of a reaction product of catecholamine, well separating PQQ, NE (noradrenaline), E (epinephrine) and products, and using UPLC-MS to identify the PQQ and the catecholamine reaction product. After proofing by results, the PQQ reacts with NE to generate the PQQNE, but does not react with E. The method has the advantages that the contents of NE in frontal lobe and hippocampus of the chronic stress induced depression model are obviously increased; by applying a certain amount of PQQ group, the content of NE is obviously decreased, and the contents of E in different groups are not obviously different; the PQQ is mainly used for regulating the catecholamine neurotransmitter through regulating the NE, but has no regulating function on E; the guidance meaning on the study of the depression disease mechanism and depression targeted medicine is realized.

The invention belongs to the field of pharmaceutical research, in particular to a method for preparing lilium total saponin extract brownie by using macroporous resin and the application thereof, aiming at extracting and purifying total lilium saponin from lilium by using macroporous resin and the application of the obtained lilium extract. The obtained lilium extract containing lilium saponins is proved by research to have the function of improving the symptoms of chronic stress depression rats, and can be used for treating human depression. The method for preparing the lilium saponins is convenient, and the prepared lilium saponin has the purity of more than 50 percent; and the invention has low cost and is easily implemented.

The invention discloses applications of a stilbene compounds for preparing medicaments for preventing and treating depression, wherein the stilbene compounds can be used as an effective active component to prepare the medicaments for preventing and treating depression. The stilbene compounds are mixtures containing ore or both of piceatannol or piceatannol 3'-O-beta-D-glucopyranoside, and used in the medicaments for preventing and treating endogenous depression, and/or reactive depression, and/or masked depression, and/or depression using learning difficulty as a characteristic; and/or secondary depression caused by medicaments, and/or secondary depression caused by body diseases, and/or postnatal depression, and/or involutional melancholia, and/or depressive neurosis. By a Konmin mouse tail suspension test, a swimming force test and a chronic stress sucrose preference determination experiment, the stilbene compounds can substantially raises disappointed time of mouse tail suspension and motionless time of forced swimming, has substantial resistant effect for interest deprivation symptom caused by chronic stress, and has a substantial antidepressant effect.

The present invention provides methods for treating anxiety or irritability in a subject. The methods comprise administering to the subject an effective amount of an antagonist of allopregnanolone (THP), or a regulator which decreases expression of the alpha 4 subunit of GABA such as gabadoxbol (THIP), or a vector comprising an isolated nucleic acid molecule encoding a mutant alpha 4 subunit GABA_A receptor protein having a neutral or non-basic amino acid residue substituted for the arginine residue at position 353 of the wild type mature protein, wherein this nucleic acid molecule is operably linked to a promoter which functions in the human brain. Such methods are useful in treating a subject undergoing a stage such as entering or having reached puberty, suffering from pre-menstrual syndrome (PMS), entering or having reached post-partem stage, entering or having reached menopause, and/or suffering from chronic stress. Also provided by the present isolated is a mutant alpha 4 subunit of GABA_A receptor protein which has a neutral or non-basic amino acid residue substituted for the arginine residue at position 353 of the wild type mature protein and an isolated nucleic acid molecule encoding this mutated protein. The present invention also provides vectors comprising a subject isolated nucleic acid molecule operably liked to a promoter which functions in prokaryotic or eukaryotic cells, as well as host cells comprising such vectors. In addition, the present invention provides methods for identifying an antagonist of THP.

The invention relates to a method for rapidly detecting the activity of catechol-oxygen-methyltransferase (COMT) in a biological sample by capillary electrophoresis, belonging to the technical fields of capillary electrophoresis detection and COMT detection. The method is used for analyzing the change of the activity of the COMT in cerebral tissues of a mouse which has chronic stress-induced oxidative damage depression and is treated by intraperitoneal injection with folic acid and different doses of pyrroloquinoline quinone (PQQ), is not reported in literature, and provides a new basis for the pathogenesis and drug action target point of the depression. The capillary electrophoresis adopted by the method is higher in analysis speed and better in separation degree, and is capable of rapidly detecting the active concentration of the COMT in the cerebral tissues; compared with the existing method for detecting the COMT, the method has the obvious advantage of not needing derivatization; compared with the methods in the literature, the method is better in reliability and selectivity and has the characteristics of high sensitivity, high analysis speed and the like.

The invention discloses an application of a frankincense extract in preparation of a vascular endothelial homeostasis maintaining medicine. The frankincense extract can be used for preparing the medicine capable of preventing damage and malfunction of a vascular endothelial cell structure due to obesity, ill living habits such as long-term smoking, drinking and the like as well as chronic stress, can be used for Preparing medicine for treating vessel wall thickening and lumen stenosis type cardiovascular diseases caused by vascular endothelial injury and matrix precipitation, and has the advantages of high activity, small toxic and side effects and low cost.

The invention discloses a medicinal composition for treating depression, which is prepared by using liquoric root, white paeony root and extracts of the liquoric root and the white paeony root as raw materials. The invention also discloses a preparation method of the medicinal composition. Experiments show that: 1, after 2 days of stomach lavaging, the medicinal composition of the invention can reduce the dead time (P is less than 0.01) and forced swimming accumulated dead time (P is less than 0.05) of a suspended tail of a tested mouse obviously, so it is deduced that the medicinal composition of the invention has experimental depression resistant effect; 2, the combined use of the extracts of the liquoric root and the white paeony root in an optimal ratio achieves an anti-depression effect more advantageous over those obtained by the single use of the liquoric root and white paeony root; and 3, the 5-HT content and NE content of the brain of a chronic stress rat are reduced obviously. The medicinal composition of the invention can improve the 5-HT content and NE content of the brain of the chronic stress rat obviously, which may be one of the mechanisms through which the medicinal composition plays an anti-depression effect.

The invention discloses a thymosin beta4 medicinal preparation for treating depression as well as a preparation method and application of the thymosin beta4 medicinal preparation, and belongs to the technical field of disease treatment. The mouse depressive behavior is induced mainly by establishing a chronic social defeat stress model (CSDS), and the model has the advantages that the model simulates social attributes in human chronic stress, and then after nasal administration of T beta 4 is conducted for seven consecutive days, the mouse depressive behavior is induced. Through a social interaction test (SIT), a tail suspension test (TST), a sucrose preference test (SPT) are and other behavioral tests are carried out to evaluate the depression level, and the result shows that T beta4 hasa rapid anti-depression effect in mice, and can reverse CSDS-induced depression-like behaviors within 7 days.